Physician profile
Vikram Gupta
NPI 1750538609
$14,552.59
in general payments reported to CMS, 2019-2025
54 companies · $2,520 in 2025
The $2,520 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $1,241 · 2021: $1,787 · 2022: $1,724 · 2023: $2,551 · 2024: $3,032 · 2025: $2,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,102.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,093.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $2,404.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,504.07 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $987.04 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $777.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $741.96 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $524.95 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Amgen INC. | $491.80 | 2019-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $453.56 | 2019-2025 | |
| Abbvie INC. | $396.95 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $291.76 | 2020-2024 | Linzess |
| Pfizer INC. | $290.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $249.58 | 2019-2024 | |
| Vifor Pharma, INC. | $227.26 | 2023-2024 | Veltassa |
| Janssen Pharmaceuticals, INC | $206.82 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.